Titre
Implementation of medication reviews into a psychiatric hospital: A monocentric, retrospective, observational study
Type
abstract de conférence/colloque
Institution
Externe
Auteur(s)
Humbert-Claude, M.
Auteure/Auteur
Attalla, N.
Auteure/Auteur
della Paolera, M.
Auteure/Auteur
Spaggiari, S.
Auteure/Auteur
Blanc, A.-L.
Auteure/Auteur
Widmer, N.
Auteure/Auteur
Liens vers les personnes
Titre du livre ou conférence/colloque
International Journal of Clinical Pharmacy
Unité
49th European Society of Clinical Pharmacy (ESCP) Virtual Symposium on Clinical Pharmacy
Adresse
October 19-21, 2021
Statut éditorial
Publié
Date de publication
2021
Volume
43
Numéro
6
Première page
1751
Dernière page/numéro d’article
1752
Peer-reviewed
Oui
Langue
anglais
Résumé
Background and Objective: Psychotropic drugs are complex, associated with potential serious adverse reactions and drug interactions. Comorbidities are frequent among psychiatric population, leading to increased vulnerability and polypharmacy. Optimizing pharmacotherapy is thereby essential. From a drug safety perspective, weekly medication reviews, in a multidisciplinary context (physicians, nurses and a clinical pharmacist) have been implemented within the psychiatric hospital units.
The aim of this study is to describe the pharmaceutical interventions (PI) carried out in a psychiatric hospital and to evaluate the impact on the routine of the clinical pharmacy unit.
Design: This retrospective, monocentric, observational study, con- sisted in the analysis of the pharmaceutical interventions (PI) collected from January 2017 to December 2020 during the medication reviews, carried out in 3 adult psychiatric and 1 psychogeriatric units (60 patients). PI have been reported according to the classification system from the Swiss Association of Public Health Administration and Hospital Pharmacists. The number of questions reaching the hotline of the clinical pharmacy unit has also been quantified. Results: The number of medication reviews increased from 13 in 2017 to 78, 107 and 125 in 2018, 2019 and 2020, respectively. The number of PI were respectively 56, 583, 893 and 870 in 2017, 2018, 2019 and 2020. The main reasons of interventions were medical questions (23%), adverse effects (15%), inappropriate duration of treatment (14%) and interactions (10%). The 4 main propositions were the same across 2018, 2019 and 2020 and consisted in providing medication information (20–27%), dosage adjustments (15–22%), monitoring (15–18%) and withdrawal of a medication (14–21 %). Depending on the year, between 59 and 75% of the propositions were accepted. Since 2017, the number of hotline questions related to psychiatry was increased by 2-fold in 2018 and 2019 and 3.8-fold in 2020. 75% came from physicians and focused on choice of treatment (19%), therapeutic alternative (18%), administration mode (17%) and dosage (16%).
Conclusion: Clinical pharmacists allow to provide safety use of psychotropic drugs and have a central role in improving therapeutic management. The increasing number of questions reaching the clinical pharmacy unit highlights the need of regular pharmaceutical support in psychotropic prescribing.
The aim of this study is to describe the pharmaceutical interventions (PI) carried out in a psychiatric hospital and to evaluate the impact on the routine of the clinical pharmacy unit.
Design: This retrospective, monocentric, observational study, con- sisted in the analysis of the pharmaceutical interventions (PI) collected from January 2017 to December 2020 during the medication reviews, carried out in 3 adult psychiatric and 1 psychogeriatric units (60 patients). PI have been reported according to the classification system from the Swiss Association of Public Health Administration and Hospital Pharmacists. The number of questions reaching the hotline of the clinical pharmacy unit has also been quantified. Results: The number of medication reviews increased from 13 in 2017 to 78, 107 and 125 in 2018, 2019 and 2020, respectively. The number of PI were respectively 56, 583, 893 and 870 in 2017, 2018, 2019 and 2020. The main reasons of interventions were medical questions (23%), adverse effects (15%), inappropriate duration of treatment (14%) and interactions (10%). The 4 main propositions were the same across 2018, 2019 and 2020 and consisted in providing medication information (20–27%), dosage adjustments (15–22%), monitoring (15–18%) and withdrawal of a medication (14–21 %). Depending on the year, between 59 and 75% of the propositions were accepted. Since 2017, the number of hotline questions related to psychiatry was increased by 2-fold in 2018 and 2019 and 3.8-fold in 2020. 75% came from physicians and focused on choice of treatment (19%), therapeutic alternative (18%), administration mode (17%) and dosage (16%).
Conclusion: Clinical pharmacists allow to provide safety use of psychotropic drugs and have a central role in improving therapeutic management. The increasing number of questions reaching the clinical pharmacy unit highlights the need of regular pharmaceutical support in psychotropic prescribing.
PID Serval
serval:BIB_9B1BFBAD42FE
Date de création
2022-01-19T16:20:43.373Z
Date de création dans IRIS
2025-05-20T22:07:11Z
Fichier(s)![Vignette d'image]()
En cours de chargement...
Nom
ESCP21_medication_reviews_psy.pdf
Version du manuscrit
published
Licence
https://creativecommons.org/licenses/by-nc-nd/4.0
Taille
1.28 MB
Format
Adobe PDF
PID Serval
serval:BIB_9B1BFBAD42FE.P001
Somme de contrôle
(MD5):e576722f52feefcb6a9d8d0e3fd77080